FCF Yield

The current FCF Yield of 7.9% means that for every $100 you invest in Zimmer Biomet, the company generates roughly $7.90 in free cash flow over the past year — free cash flow being the cash left after operating expenses and capital investments.

This yield places the company well above its healthcare sector median of 3.6%, ranking it in the 86th percentile among peers. The year-over-year change is not available, but the quarter-over-quarter change shows a decline of 4.8%, from 8.3% to 7.9%. While the absolute level remains high and attractive versus peers, the recent quarterly decline suggests the cash generation efficiency may be under slight pressure. The combination of a strong yield with a short-term downward trend implies a moderate risk that the metric could continue to erode, even if the current valuation still offers a buffer. This metric supports the NEUTRAL verdict by showing a compelling free cash flow profile that is not offset by a clear positive trend, leaving the stock fairly balanced rather than clearly undervalued or overvalued.

Frequently Asked Questions

Closest Sector Peers